Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

6.97

+0.25

(+3.72%)

As of 12:22PM EDT. Market open.

Trade prices are not sourced from all markets

All

Zacks
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
GlobeNewswire
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical